肿瘤标志物联合检测在肺癌分型中的应用价值

The application of combined detection of tumor markers in the classification of lung cancer

目的通过肿瘤标志物联合检测,评价血清癌胚抗原(CEA)、糖类抗原(CA)50、CA125、CA153、鳞状细胞癌抗原(SCCA)、细胞角蛋白19片段(CYFRA21-1)、胃泌素释放肽前体(ProGRP)、神经元特异性烯醇化酶(NSE)水平在肺癌分型中的临床价值。方法用化学发光法测定了80例肺癌患者血清CEA、CA50、CA125、CA153、SCCA、CYFRA21-1、ProGRP、NSE水平,探讨了该8项肿瘤标志物在肺癌组织分型中的应用价值。结果小细胞肺癌(SCLC)患者NSE、ProGRP水平分别为(356.7±298.7)pg/mL和(52.03±28.98)μg/L,明显高于非小细胞肺癌(NSCLC)患者的(22.7±11.9)pg/mL和(37.01±18.01)μg/L,而CEA、CA50、CA125、CA153水平明显高于肺鳞癌,NSCLC患者明显高于SCLC患者。SCCA是肺鳞癌较特异的标志物,在判别SCLC与NSCLC类型中,CYFRA21-1是NSCLC最灵敏的肿瘤指标。结论该8项肿瘤标志物联合检测在肺癌组织分型方面可为临床提供有价值的参考资料。

Objective To evaluate the clinical value of serum carcino-embryonic antigen（CEA）,carbohydrate antigen（CA）50,CA125,CA153,squamous cell carcinoma antigen（SCCA）,cytokeratin 19 fragment（CYFRA21-1）,gastrin-releasing peptide（ProGRP） and neuron-specific enolase（NSE） levels in the classification of lung cancer.Methods We tested CEA,CA50,CA125,CA153,SCCA,CYFRA21-1,ProGRP,NSE levels of 80 cases of lung cancer patients by chemiluminescence,and discussed clinical value of eight tumor markers in the classification of lung cancer.Results NSE,ProGRP levels were significantly higher than those in the small cell lung cancer（SCLC）,and CEA,CA50,CA125 and CA153 levels were significantly higher in adenocarcinoma of the lung than those in squamous cell lung cancer patients and significantly lower than those in NSCLC patients.SCCA was a specific marker of squamous cell lung cancer,and CYFRA21-1 was the most sensitive tumor marker in the classification of the SCLC and NSCLC types.Conclusion The joint detection of eight tumor markers is clinically valuable in the classification of lung cancer.